{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:49:26Z","timestamp":1775062166047,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bmc.2022.117004","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T03:19:04Z","timestamp":1663211944000},"page":"117004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"73","author":[{"given":"Mohamed","family":"Samir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa H.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.I.","family":"Elbastawesy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamada Mohamed","family":"Halby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal El-Din A.","family":"Abuo-Rahma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.117004_b0005","first-page":"1","article-title":"Thiazolidine-2, 4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities","volume":"1","author":"Aziz","year":"2021","journal-title":"Mol Divers"},{"key":"10.1016\/j.bmc.2022.117004_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114021","article-title":"Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects","volume":"228","author":"Ibrahim","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116674","article-title":"Recent insight into the biological activities and SAR of quinolone derivatives as multifunctional scaffold","volume":"59","author":"Sharma","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/antibiotics11010088","article-title":"Antimicrobial bacillus: Metabolites and their mode of action","volume":"11","author":"Tran","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.bmc.2022.117004_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-020-00669-3","article-title":"A review on quinoline derivatives as anti-methicillin resistant staphylococcus aureus (MRSA) agents","volume":"14","author":"Kumar","year":"2020","journal-title":"BMC Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0030","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2174\/0929867324666171106160326","article-title":"New strategy on antimicrobial-resistance: Inhibitors of DNA replication enzymes","volume":"26","author":"Yi","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0035","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.3390\/molecules26092671","article-title":"New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives","volume":"26","author":"Terreni","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.117004_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113340","article-title":"Membrane active 7-thiazoxime quinolones as novel DNA binding agents to decrease the genes expression and exert potent anti-methicillin-resistant staphylococcus aureus activity","volume":"217","author":"Chen","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0045","doi-asserted-by":"crossref","first-page":"113741","DOI":"10.1016\/j.ejmech.2021.113741","article-title":"The antibacterial activity of fluoroquinolone derivatives: An update (2018\u20132021)","volume":"224","author":"Jia","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0050","first-page":"134","article-title":"Recent strategies in design of antitumor and antibacterial fluoroquinolones","volume":"4","author":"Samir","year":"2021","journal-title":"JABPS"},{"key":"10.1016\/j.bmc.2022.117004_b0055","doi-asserted-by":"crossref","first-page":"104658","DOI":"10.1016\/j.bioorg.2021.104658","article-title":"Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent ciprofloxacin derivatives","volume":"108","author":"Alsughayer","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0060","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.bmc.2019.06.017","article-title":"Discovery and development of DNA polymerase IIIC inhibitors to treat gram-positive infections","volume":"27","author":"Xu","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0065","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1021\/acs.jmedchem.2c00039","article-title":"The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV","volume":"65","author":"Kokot","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0070","first-page":"1","article-title":"Emerging quinoline-and quinolone-based antibiotics in the light of epidemics","volume":"00","author":"Kaur","year":"2022","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2022.117004_b0075","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1093\/nar\/18.24.7381","article-title":"Development of novel inhibitor probes of DNA polymerase III based on dGTP analogs of the HPUra type: base, nucleoside and nucleotide derivatives of N 2-(3, 4-dichlorobenzyl) guanine","volume":"18","author":"Butler","year":"1990","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2022.117004_b0080","first-page":"377","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"MMBR"},{"key":"10.1016\/j.bmc.2022.117004_b0085","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/jm0510023","article-title":"Hybrid antibacterials. DNA polymerase\u2212 topoisomerase inhibitors","volume":"49","author":"Zhi","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/AAC.01311-05","article-title":"Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound","volume":"51","author":"Butler","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2022.117004_b0095","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1002\/anie.201209979","article-title":"Combating multidrug-resistant bacteria: Current strategies for the discovery of novel antibacterials","volume":"52","author":"O'Connell","year":"2013","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2022.117004_b0100","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/jo50006a010","article-title":"Synthesis of 1-mono-and 1, 3-di-substituted 6-aminouracils. Diuretic activity","volume":"16","author":"Papesch","year":"1951","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0105","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1016\/0040-4039(91)80214-Q","article-title":"Synthesis of 3-substituted 6-aminouracils","volume":"32","author":"M\u00fcller","year":"1991","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2022.117004_b0110","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1021\/jm701159t","article-title":"Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists","volume":"51","author":"Cosimelli","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0115","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1134\/S1070428017120235","article-title":"Halocyclization of 2-Allyl (propargyl) sulfanyl-6-aminopyrimidin-4 (3H)-ones","volume":"53","author":"Kim","year":"2017","journal-title":"Russ J Org Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0120","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1016\/j.tet.2011.05.056","article-title":"Novel synthesis approach and antiplatelet activity evaluation of 6- alkylamino-2, 4-dialkyl (aryl) thiopyrimidines","volume":"67","author":"Liu","year":"2011","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2022.117004_b0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jhet.5570010108","article-title":"Aromaticity in heterocyclic systems. II. The application of NMR in a study of the synthesis and structure of certain lmidazo [1, 2\u2010c] pyrimidines and related pyrrolo [2, 3\u2010d] pyrimidines","volume":"1","author":"Noell","year":"1964","journal-title":"J Heterocycl Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0130","first-page":"39","article-title":"Efficient utilization of 6-aminouracil to synthesize fused and related heterocyclic compounds and their evaluation as prostate cytotoxic agents with cathepsin B inhibition","volume":"4","author":"Sarg","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0135","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1016\/j.bmc.2009.06.053","article-title":"7-((4-substituted) piperazin-1-yl) derivatives of ciprofloxacin: Synthesis and in vitro biological evaluation as potential antitumor agents","volume":"17","author":"Az\u00e9ma","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0140","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkn090","article-title":"Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method","volume":"61","author":"Bonev","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2022.117004_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113056","article-title":"Potentials of nanotechnology in treatment of methicillin-resistant staphylococcus aureus","volume":"213","author":"Gao","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117004_b0150","doi-asserted-by":"crossref","first-page":"127995","DOI":"10.1016\/j.bmcl.2021.127995","article-title":"Unique para-aminobenzenesulfonyl oxadiazoles as novel structural potential membrane active antibacterial agents towards drug-resistant methicillin resistant staphylococcus aureus","volume":"41","author":"Wang","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2022.117004_b0155","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2147\/IDR.S306648","article-title":"Prevalence and Associated Factors of Methicillin Resistance Staphylococcus aureus (MRSA) Among Urinary Tract Infection Suspected Patients Attending at Arba Minch General Hospital, Southern Ethiopia","volume":"14","author":"Mitiku","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.bmc.2022.117004_b0160","first-page":"31","article-title":"Novel approaches for the treatment of methicillin- resistant staphylococcus aureus: Using nanoparticles to overcome multidrug resistance","volume":"26","author":"Vanamala","year":"2021","journal-title":"Drug Discov"},{"key":"10.1016\/j.bmc.2022.117004_b0165","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/molecules26051234","article-title":"Towards conformation-sensitive inhibition of gyrase: Implications of mechanistic insight for the identification and improvement of inhibitors","volume":"26","author":"Klostermeier","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.117004_b0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jac\/41.4.481","article-title":"Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12\u20138039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus","volume":"41","author":"Schmitz","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2022.117004_b0175","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.43.11.2710","article-title":"Mechanisms of fluoroquinolone transport by human neutrophils","volume":"43","author":"Walters","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2022.117004_b0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/antibiotics7020032","article-title":"Our evolving understanding of the mechanism of quinolones","volume":"7","author":"Gutierrez","year":"2018","journal-title":"Antibiotics"},{"key":"10.1016\/j.bmc.2022.117004_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-2918(00)88266-1","article-title":"Expanded activity and utility of the new fluoroquinolones: A review","volume":"21","author":"Blandeau","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.bmc.2022.117004_b0190","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ajcp\/11.5.414","article-title":"Studies with the agar cup-plate method: IV. A correlation of agar cup-plate data with antiseptic dilution data","volume":"11","author":"Miller","year":"1941","journal-title":"Am J Clin Pathol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622003972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622003972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:20:00Z","timestamp":1760836800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622003972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"alternative-id":["S0968089622003972"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117004","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117004"}}